Pacific Biosciences of California Total Assets
Pacific Biosciences of California total assets. Based on the latest financial reports, Pacific Biosciences of California (PACB) holds total assets worth $751.85 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see PACB stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Pacific Biosciences of California (2008–2025)
Total assets of Pacific Biosciences of California from 2008 to 2025. This chart illustrates how Pacific Biosciences of California's total assets have evolved over time, based on quarterly financial data. See PACB stock price and chart for real-time trading data and today's change.
Pacific Biosciences of California - Asset Composition Analysis
Pacific Biosciences of California Total Assets Breakdown (December 2025)
Pacific Biosciences of California total assets breakdown as of December 2025. Pacific Biosciences of California's total assets of $751.85 Million consist of 47.8% current assets and 52.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.1% |
| Accounts Receivable | $35.45 Million | 4.5% |
| Inventory | $49.28 Million | 6.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $15.12 Million | 1.9% |
| Goodwill | $317.76 Million | 40.5% |
Asset Composition Trend (2008–2025)
This chart illustrates how Pacific Biosciences of California's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Pacific Biosciences of California to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pacific Biosciences of California's current assets represent 47.8% of total assets in 2025, a decrease from 94.5% in 2008.
- Cash Position: Cash and equivalents constituted 8.1% of total assets in 2025, down from 69.4% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 41.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is goodwill at 40.5% of total assets.
Pacific Biosciences of California Competitors by Total Assets
Key competitors of Pacific Biosciences of California based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
BMC Medical Co. Ltd. A
SHE:301367
|
China | CN¥3.59 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
|
Hironic Co. Ltd
KQ:149980
|
Korea | ₩80.01 Billion |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
Pacific Biosciences of California - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.92 | 6.92 | 20.32 |
| Quick Ratio | 4.03 | 6.02 | 19.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $269.83 Million | $353.64 Million | $1.07 Billion |
Pacific Biosciences of California - Advanced Valuation Insights
This section examines the relationship between Pacific Biosciences of California's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 170.66 |
| Latest Market Cap to Assets Ratio | 0.91 |
| Asset Growth Rate (YoY) | -37.8% |
| Total Assets | $784.08 Million |
| Market Capitalization | $714.91 Million USD |
Valuation Analysis
Near Book Valuation: The market values Pacific Biosciences of California's assets close to their book value (0.91x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Pacific Biosciences of California's assets decreased by 37.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pacific Biosciences of California (2008–2025)
The table below shows the annual total assets of Pacific Biosciences of California from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $784.08 Million | -37.79% |
| 2024-12-31 | $1.26 Billion | -27.81% |
| 2023-12-31 | $1.75 Billion | -1.19% |
| 2022-12-31 | $1.77 Billion | -11.95% |
| 2021-12-31 | $2.01 Billion | +384.80% |
| 2020-12-31 | $413.98 Million | +179.74% |
| 2019-12-31 | $147.99 Million | -13.09% |
| 2018-12-31 | $170.28 Million | +18.18% |
| 2017-12-31 | $144.08 Million | +4.50% |
| 2016-12-31 | $137.88 Million | +5.17% |
| 2015-12-31 | $131.11 Million | +5.29% |
| 2014-12-31 | $124.52 Million | -8.56% |
| 2013-12-31 | $136.19 Million | +5.01% |
| 2012-12-31 | $129.68 Million | -40.60% |
| 2011-12-31 | $218.32 Million | -28.60% |
| 2010-12-31 | $305.75 Million | +202.43% |
| 2009-12-31 | $101.10 Million | -10.62% |
| 2008-12-31 | $113.11 Million | -- |
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stran… Read more